{"id":"botulinum-toxin-type-a-300u","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting acetylcholine release, botulinum toxin Type A reduces muscle spasms and contractions, providing relief for conditions such as blepharospasm and cervical dystonia.","oneSentence":"Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:48.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02051933","phase":"NA","title":"The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-01","conditions":"Equinus Contracture","enrollment":10},{"nctId":"NCT03320850","phase":"PHASE2","title":"BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-10-04","conditions":"Urinary Incontinence, Overactive Bladder With Urinary Incontinence","enrollment":383},{"nctId":"NCT00876447","phase":"PHASE3","title":"A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01-01","conditions":"Overactive Bladder","enrollment":397},{"nctId":"NCT03905304","phase":"PHASE3","title":"Efficacy and Safety of MEDITOXIN® in Cervical Dystonia","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2013-01-09","conditions":"Cervical Dystonia","enrollment":152},{"nctId":"NCT02145676","phase":"PHASE3","title":"OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05","conditions":"Muscle Spasticity, Stroke","enrollment":53},{"nctId":"NCT01682603","phase":"PHASE2","title":"Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-09","conditions":"Spinal Cord Injuries","enrollment":34},{"nctId":"NCT02179099","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients","status":"TERMINATED","sponsor":"UroGen Pharma Ltd.","startDate":"2014-07","conditions":"Overactive Bladder","enrollment":3},{"nctId":"NCT00311376","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Overactive Bladder","enrollment":416},{"nctId":"NCT00461292","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-05","conditions":"Overactive Bladder","enrollment":275},{"nctId":"NCT00439140","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-06","conditions":"Overactive Bladder","enrollment":41},{"nctId":"NCT01091727","phase":"PHASE3","title":"Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2006-10","conditions":"Neurogenic Detrusor Overactivity","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®"],"phase":"phase_3","status":"active","brandName":"botulinum toxin Type A (300U)","genericName":"botulinum toxin Type A (300U)","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"Botulinum toxin Type A (300U) has been studied for its potential to treat conditions such as Equinus Contracture, Overactive Bladder, Cervical Dystonia, Urinary Incontinence, and Overactive Bladder With Urinary Incontinence. The mechanism of action of botulinum toxin Type A is not specified in the provided facts, but it is known to be used as an intervention in various clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}